主动免疫疗法治疗胶质母细胞瘤的系统评价和荟萃分析。
Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis.
机构信息
Department of Neurosurgery, 95449Dr Soetomo General Academic Hospital, Surabaya, Indonesia.
95449Faculty of Medicine - Universitas Airlangga, Surabaya, Indonesia.
出版信息
Cancer Control. 2022 Jan-Dec;29:10732748221079474. doi: 10.1177/10732748221079474.
INTRODUCTION
Glioblastoma multiforme (GBM) makes 60-70% of gliomas and 15% of primary brain tumors. Despite the availability of standard multimodal therapy, 2 years, 3 years, and 5 years survival rate of GBM are still low. Active immunotherapy is a relatively new treatment option for GBM that seems promising.
METHODS
An electronic database search on PubMed, Cochrane, Scopus, and clinicaltrials.gov was performed to include all relevant studies. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Reported parameters are OS, PFS, AEs, post treatment KPS, and 2 year mortality.
RESULTS
Active immunotherapy provided better OS (HR = .85; 95% CI = .71-1.01; = .06) and PFS (HS = .83; 95% CI= .66 - 1.03; = .11) side albeit not statistically significant. Active immunotherapy reduces the risk of 2 year mortality as much as 2.5% compared to control group (NNT and RRR was 56.7078 and 0,0258, respectively).
CONCLUSION
Active immunotherapy might be beneficial in terms of survival rate in patients with GBM although not statistically significant. It could be a treatment option for GBM in the future.
简介
多形性胶质母细胞瘤（GBM）占神经胶质瘤的 60-70%，占原发性脑肿瘤的 15%。尽管有标准的多模式治疗，GBM 的 2 年、3 年和 5 年生存率仍然较低。主动免疫疗法是一种相对较新的治疗 GBM 的方法，似乎很有前途。
方法
在 PubMed、Cochrane、Scopus 和 clinicaltrials.gov 上进行电子数据库检索，以纳入所有相关研究。本研究按照系统评价和荟萃分析的首选报告项目（PRISMA）进行。报告的参数是 OS、PFS、AE、治疗后 KPS 和 2 年死亡率。
结果
主动免疫治疗提供了更好的 OS（HR =.85；95% CI =.71-1.01； =.06）和 PFS（HS =.83；95% CI=.66 - 1.03； =.11），尽管没有统计学意义。与对照组相比，主动免疫治疗降低了 2 年死亡率高达 2.5%（NNT 和 RRR 分别为 56.7078 和 0.0258）。
结论
主动免疫疗法可能对 GBM 患者的生存率有益，尽管没有统计学意义。它可能是未来 GBM 的一种治疗选择。
Zotero 插件